Kedudukan dalam Saham
#29740
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Harga Saham
$3.14
Disegerakkan terakhir: 2026-08-18
Perubahan (1 tahun)
3.29%
Perdagangan Evaxion Biotech A/S (EVAX)
Harga EVAX dengan permodalan pasaran b
Modal pasaran bagi Evaxion Biotech A/S(EVAX)
Modal Pasaran: $19.83M
Sehingga August 2026, Evaxion Biotech A/S mempunyai modal pasaran sebanyak $19.83M. Ini menjadikan Evaxion Biotech A/S syarikat ke-29740th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Evaxion Biotech A/S dari 2021 hingga 2026
EVAX berbanding dengan 5 teratas yang paling popular stocks
| Harga EVAX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.307T
|
+26,754,815.74%
|
|
|
|
|
$4.551T
|
+22,943,949.74%
|
|
|
|
|
$4.154T
|
+20,945,524.83%
|
|
|
|
|
$3.589T
|
+18,092,768.75%
|
|
|
|
|
$2.797T
|
+14,101,147.13%
|
